ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-β pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis

Anne M. Fagan, Erin Christopher, Jennie W. Taylor, Maia Parsadanian, Michael Spinner, Melanie Watson, John D. Fryer, Suzanne Wahrle, Kelly R. Bales, Steven M. Paul, David M. Holtzman

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Epidemiological studies suggest links between cholesterol metabolism and Alzheimer's disease (AD), with hypercholesterolemia associated with increased AD risk, and use of cholesterol-lowering drugs associated with decreased risk. Animal models using cholesterol-modifying dietary or pharmacological interventions demonstrate similar findings. Proposed mechanisms include effects of cholesterol on the metabolism of amyloid-β (Aβ), the protein that deposits in AD brain. To investigate the effect of genetic alterations in plasma cholesterol on Aβ pathology, we crossed the PDAPP transgenic mouse model of AD-like cerebral amyloidosis to apolipoprotein AI-null mice that have markedly reduced plasma cholesterol levels due to a virtual absence of high density lipoproteins, the primary lipoprotein in mice. Interestingly and in contrast to models using non-physiological high fat diets or cholesterol-lowering drugs to modify plasma cholesterol, we observed no differences in Aβ pathology in PDAPP mice of the various apoAI genotypes despite robust differences in plasma cholesterol levels between the groups. Absence of apoAI also resulted in reductions in brain but not cerebrospinal fluid cholesterol, but had no effect on brain apolipoprotein E levels. These and other data suggest that it is perhaps the level of brain apolipoprotein E, not cholesterol per se, that plays a primary role in brain Aβ metabolism.

Original languageEnglish (US)
Pages (from-to)1413-1422
Number of pages10
JournalAmerican Journal of Pathology
Volume165
Issue number4
StatePublished - Oct 2004
Externally publishedYes

Fingerprint

Amyloid
Alzheimer Disease
Cholesterol
Pathology
Brain
Apolipoproteins E
Amyloid angiopathy
Dietary Cholesterol
Serum Amyloid A Protein
Apolipoprotein A-I
High Fat Diet
HDL Lipoproteins
Hypercholesterolemia
Pharmaceutical Preparations
Transgenic Mice
Lipoproteins
Cerebrospinal Fluid
Epidemiologic Studies
Animal Models
Genotype

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Fagan, A. M., Christopher, E., Taylor, J. W., Parsadanian, M., Spinner, M., Watson, M., ... Holtzman, D. M. (2004). ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-β pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis. American Journal of Pathology, 165(4), 1413-1422.

ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-β pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis. / Fagan, Anne M.; Christopher, Erin; Taylor, Jennie W.; Parsadanian, Maia; Spinner, Michael; Watson, Melanie; Fryer, John D.; Wahrle, Suzanne; Bales, Kelly R.; Paul, Steven M.; Holtzman, David M.

In: American Journal of Pathology, Vol. 165, No. 4, 10.2004, p. 1413-1422.

Research output: Contribution to journalArticle

Fagan, AM, Christopher, E, Taylor, JW, Parsadanian, M, Spinner, M, Watson, M, Fryer, JD, Wahrle, S, Bales, KR, Paul, SM & Holtzman, DM 2004, 'ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-β pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis', American Journal of Pathology, vol. 165, no. 4, pp. 1413-1422.
Fagan, Anne M. ; Christopher, Erin ; Taylor, Jennie W. ; Parsadanian, Maia ; Spinner, Michael ; Watson, Melanie ; Fryer, John D. ; Wahrle, Suzanne ; Bales, Kelly R. ; Paul, Steven M. ; Holtzman, David M. / ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-β pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis. In: American Journal of Pathology. 2004 ; Vol. 165, No. 4. pp. 1413-1422.
@article{f71addde28b8487cb9230a36b51f0810,
title = "ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-β pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis",
abstract = "Epidemiological studies suggest links between cholesterol metabolism and Alzheimer's disease (AD), with hypercholesterolemia associated with increased AD risk, and use of cholesterol-lowering drugs associated with decreased risk. Animal models using cholesterol-modifying dietary or pharmacological interventions demonstrate similar findings. Proposed mechanisms include effects of cholesterol on the metabolism of amyloid-β (Aβ), the protein that deposits in AD brain. To investigate the effect of genetic alterations in plasma cholesterol on Aβ pathology, we crossed the PDAPP transgenic mouse model of AD-like cerebral amyloidosis to apolipoprotein AI-null mice that have markedly reduced plasma cholesterol levels due to a virtual absence of high density lipoproteins, the primary lipoprotein in mice. Interestingly and in contrast to models using non-physiological high fat diets or cholesterol-lowering drugs to modify plasma cholesterol, we observed no differences in Aβ pathology in PDAPP mice of the various apoAI genotypes despite robust differences in plasma cholesterol levels between the groups. Absence of apoAI also resulted in reductions in brain but not cerebrospinal fluid cholesterol, but had no effect on brain apolipoprotein E levels. These and other data suggest that it is perhaps the level of brain apolipoprotein E, not cholesterol per se, that plays a primary role in brain Aβ metabolism.",
author = "Fagan, {Anne M.} and Erin Christopher and Taylor, {Jennie W.} and Maia Parsadanian and Michael Spinner and Melanie Watson and Fryer, {John D.} and Suzanne Wahrle and Bales, {Kelly R.} and Paul, {Steven M.} and Holtzman, {David M.}",
year = "2004",
month = "10",
language = "English (US)",
volume = "165",
pages = "1413--1422",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-β pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis

AU - Fagan, Anne M.

AU - Christopher, Erin

AU - Taylor, Jennie W.

AU - Parsadanian, Maia

AU - Spinner, Michael

AU - Watson, Melanie

AU - Fryer, John D.

AU - Wahrle, Suzanne

AU - Bales, Kelly R.

AU - Paul, Steven M.

AU - Holtzman, David M.

PY - 2004/10

Y1 - 2004/10

N2 - Epidemiological studies suggest links between cholesterol metabolism and Alzheimer's disease (AD), with hypercholesterolemia associated with increased AD risk, and use of cholesterol-lowering drugs associated with decreased risk. Animal models using cholesterol-modifying dietary or pharmacological interventions demonstrate similar findings. Proposed mechanisms include effects of cholesterol on the metabolism of amyloid-β (Aβ), the protein that deposits in AD brain. To investigate the effect of genetic alterations in plasma cholesterol on Aβ pathology, we crossed the PDAPP transgenic mouse model of AD-like cerebral amyloidosis to apolipoprotein AI-null mice that have markedly reduced plasma cholesterol levels due to a virtual absence of high density lipoproteins, the primary lipoprotein in mice. Interestingly and in contrast to models using non-physiological high fat diets or cholesterol-lowering drugs to modify plasma cholesterol, we observed no differences in Aβ pathology in PDAPP mice of the various apoAI genotypes despite robust differences in plasma cholesterol levels between the groups. Absence of apoAI also resulted in reductions in brain but not cerebrospinal fluid cholesterol, but had no effect on brain apolipoprotein E levels. These and other data suggest that it is perhaps the level of brain apolipoprotein E, not cholesterol per se, that plays a primary role in brain Aβ metabolism.

AB - Epidemiological studies suggest links between cholesterol metabolism and Alzheimer's disease (AD), with hypercholesterolemia associated with increased AD risk, and use of cholesterol-lowering drugs associated with decreased risk. Animal models using cholesterol-modifying dietary or pharmacological interventions demonstrate similar findings. Proposed mechanisms include effects of cholesterol on the metabolism of amyloid-β (Aβ), the protein that deposits in AD brain. To investigate the effect of genetic alterations in plasma cholesterol on Aβ pathology, we crossed the PDAPP transgenic mouse model of AD-like cerebral amyloidosis to apolipoprotein AI-null mice that have markedly reduced plasma cholesterol levels due to a virtual absence of high density lipoproteins, the primary lipoprotein in mice. Interestingly and in contrast to models using non-physiological high fat diets or cholesterol-lowering drugs to modify plasma cholesterol, we observed no differences in Aβ pathology in PDAPP mice of the various apoAI genotypes despite robust differences in plasma cholesterol levels between the groups. Absence of apoAI also resulted in reductions in brain but not cerebrospinal fluid cholesterol, but had no effect on brain apolipoprotein E levels. These and other data suggest that it is perhaps the level of brain apolipoprotein E, not cholesterol per se, that plays a primary role in brain Aβ metabolism.

UR - http://www.scopus.com/inward/record.url?scp=4644269609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644269609&partnerID=8YFLogxK

M3 - Article

C2 - 15466405

AN - SCOPUS:4644269609

VL - 165

SP - 1413

EP - 1422

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 4

ER -